XML 80 R63.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration, Licensing and Other Arrangements - Additional Information (Detail 1) - USD ($)
$ in Millions
Dec. 31, 2020
May 31, 2018
Dec. 31, 2016
Collaboration and License Agreement | Receptor CLA | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2017-01-01      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue recognition period     4 years
Deferred revenue - nonrefundable license fee     $ 1.0
Collaboration and License Agreement | United Therapeutics Corporation      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue - nonrefundable license fee $ 105.8    
Collaboration and License Agreement | United Therapeutics Corporation | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2018-10-01      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue recognition period 39 months    
License and Distribution Agreement | Cipla Ltd | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2018-06-01      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue recognition period   15 years  
Deferred revenue - nonrefundable license fee   $ 2.2